Careers

Biomarkers Alzheimers Disease CSF

Affiches Jun 16, 2013

Neurosciences

Spectrométrie de masse

June 16, 2013

Daniel S. Spellman¹, Kristin R. Wildsmith², Lee Honigberg², Angus C. Nairn³, Judith A. Siuciak4,7, Mitchell A. Kling5, Howard Schulman6, Michael Schirm6, Daniel Chelsky6, William Z. Potter4,7. Alzheimer’s Disease Neuroimaging Initiative (ADNI) and Foundation for NIH (FNIH) Biomarkers Consortium CSF Proteomics Project Team.

Evaluation of a Multiplexed Mass Spectrometry-Based Method for Measuring Candidate Peptide Biomarkers in Alzheimer’s Disease Neuroimaging Initiative (ADNI) CSF, ASMS 2013.

Affiches

Apr 14, 2026

Understanding Protein Normalization: A Case Study in PBMC Fit-for-Purpose Validation by MS

Affiches

Mar 3, 2026

Challenging Hybrid Affinity Approach: Streamlined Total Antibody Quantitation with Uncompromised Sensitivity

Affiches

Mar 3, 2026

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

CellCarta has the multi-modal capabilities, scientific depth, and harmonized global footprint needed to advance even the most complex programs in precision medicine.

Biomarkers Alzheimers Disease CSF

Featured Resources

Understanding Protein Normalization: A Case Study in PBMC Fit-for-Purpose Validation by MS

Challenging Hybrid Affinity Approach: Streamlined Total Antibody Quantitation with Uncompromised Sensitivity

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

One global CRO for your whole therapeutic development journey